Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Latest filing published 18 Sept 2026 for CRESCENT BIOPHARMA, INC., €9,621.
Filing timeline
BuySaleBarbara Harlin Bispham
Insider track record
Disclosed buys
0
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Barbara Harlin Bispham: trading record in brief
Barbara Harlin Bispham discloses dealings in Crescent Biopharma, Inc. to SEC (Form 4). Over a trading history stretching from 15 December 2025 to 16 September 2026, the count stands at 4 filings.
On the market, this insider has only sold: 2 sales, €29k in total. Other entries cover 2 share grants. In 2026 alone, the filings show no purchases and 2 sales.
Most recently, on 18 September 2026, the filings show an open-market sale worth €9,621 in Crescent Biopharma, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Barbara Harlin Bispham
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
620 shares@ US$17.90Ordinary SharesSEC:0001628280-26-062703:0
1,218 sharesOrdinary SharesSEC:0001628280-26-044887:0
12,422 sharesOrdinary SharesSEC:0001628280-25-057669:0
3 of 3 declarations
